A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 67, Issue 4, 2008, Pages 478-484

  Miceli Richard, C ^a   Comets, E ^b,c   Verstuyft, C ^d   Tamouza, R ^b   Loiseau, P ^b   Ravaud, P ^b,c,e   Kupper, H ^f   Becquemont, L ^d   Charron, D ^b   Mariette, Xavier ^a  

^a BICÊTRE HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e BICHAT HOSPITAL   (France)

^f ABBOTT GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPITOPE; HLA DR ANTIGEN; METHOTREXATE; TUMOR NECROSIS FACTOR;

ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE FREQUENCY; GENE LOCUS; GENOTYPE; HAPLOTYPE; HEREDITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HAPLOTYPES; HLA-DR ANTIGENS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41849134745     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.074104     Document Type: Article

References (30)

1. Padyukov L, Lampa J, Heimburger M, Ernestam S, Cederholm T, Lundkvist I, et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003;62:526-9.
2. Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 2004;50:2750-6.
3. Mascheretti S, Hampe J, Kuhbacher T, Herfarth H, Krawczak M, Folsch UR, et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J 2002;2:127-36.
4. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003;48:1849-52.
5. Cuchacovich M, Ferreira L, Aliste M, Soto L, Cuenca J, Cruzat A, et al. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand J Rheumatol 2004;33:228-32.
6. Martinez A, Salido M, Bonilla G, Pascual-Salcedo D, Fernandez-Arquero M, de Miguel S, et al. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum 2004;50:1077-82.
7. Mugnier B, Roudier J. Tumor necrosis factor alpha haplotypes versus tumor necrosis factor alpha -308 G/A polymorphism in the prediction of infliximab treatment efficacy in rheumatoid arthritis. Arthritis Rheum 2004;50:4075-6; author reply 6-7.
8. Fonseca JE, Carvalho T, Cruz M, Nero P, Sobral M, Mourao AF, et al. Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann Rheum Dis 2005;64:793-4.
9. Kang CP, Lee KW, Yoo DH, Kang C, Bae SC. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford) 2005;44:547-52.
10. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG. Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int 2006;27:157-61.
11. Marotte H, Pallot-Prades B, Grange L, Tebib J, Gaudin P, Alexandre C, et al. The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis 2006;65:342-7.
12. Seitz M, Wirthmuller U, Moller B, Villiger PM. The -308 tumour necrosis factor-{alpha} gene polymorphism predicts therapeutic response to TNF{alpha}-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2007;46:93-6.
13. Burmester GR MX, Montecucco C, Monteagudo-Saez I, Malaise M, Tzioufas, AG BJ, Unnebrink K, Kary S, Kupper H. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007;66:732-9.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
15. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
16. Mullighan CG, Fanning GC, Chapel HM, Welsh KI. TNF and lymphotoxin-alpha polymorphisms associated with common variable immunodeficiency: role in the pathogenesis of granulomatous disease. J Immunol 1997;159:6236-41.
17. Simmonds MJ, Heward JM, Howson JM, Foxall H, Nithiyananthan R, Franklyn JA, et al. A systematic approach to the assessment of known TNF-alpha polymorphisms in Graves' disease. Genes Immun 2004;5:267-73.
18. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30:1205-13.
19. Gorman JD, Lum RF, Chen JJ, Suarez-Almazor ME, Thomson G, Criswell LA. Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patients. Arthritis Rheum 2004;50:400-12.
20. Stephens JC, Schneider JA, Tanguay DA, Choi J, Acharya T, Stanley SE, et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science 2001;293:489-93.
21. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-9.
22. Bouma G, Crusius JB, Oudkerk Pool M, Kolkman JJ, von Blomberg BM, Kostense PJ, et al. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996;43:456-63.
23. Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998;113:401-6.
24. Tang GJ, Huang SL, Yien HW, Chen WS, Chi CW, Wu CW, et al. Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med 2000;28:2733-6.
25. Fernandes H, Koneru B, Fernandes N, Hameed M, Cohen MC, Raveche E, et al. Investigation of promoter polymorphisms in the tumor necrosis factor-alpha and interleukin-10 genes in liver transplant patients. Transplantation 2002;73:1886-91.
26. Huizinga TW, Westendorp RG, Bollen EL, Keijsers V, Brinkman BM, Langermans JA, et al. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 1997;72:149-53.
27. Kubota T, McNamara DM, Wang JJ, Trost M, McTiernan CF, Mann DL, et al. Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. VEST Investigators for TNF Genotype Analysis. Vesnarinone Survival Trial. Circulation 1998;97:2499-501.
28. de Jong BA, Westendorp RG, Bakker AM, Huizinga TW. Polymorphisms in or near tumour necrosis factor (TNF)-gene do not determine levels of endotoxin-induced TNF production. Genes Immun 2002;3:25-9.
29. Marotte H, Maslinski W, Miossec P. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther 2005;7:R149-55.
30. Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vickenoog M, Smeets TJM, Dinant H, et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pre-treatment TNFα expression in the synovium. Ann Rheum Dis 2007; Epub ahead of print 29 November 2007. doi:10.1136/ard.2007.080440